Valproate monotherapy in children.
Seizures are more common in children than in adults. Since most pediatric epilepsies can be controlled with a single antiepileptic drug, children with epilepsy should receive monotherapy when possible or switch from polytherapy to monotherapy. More than half of the epileptic patients receiving multiple antiepileptic drugs will have better seizure control as well as fewer side effects with monotherapy. Most of the pediatric epilepsies occur as primary generalized seizures, for which valproate is a preferred drug. Children can begin to receive valproate treatment in a dosage of 20 to 30 mg/kg per day in two or three divided doses. After several days, plasma levels may be useful in adjusting the dosage. The major adverse effect of valproate in children is fatal hepatotoxicity. The risk of this complication is considerably lower with valproate monotherapy (one per 10,000 patients) than with polytherapy. Other advantages of valproate monotherapy, compared with polytherapy, include the avoidance of drug interactions, lower cost, and reduced potential for impaired cognitive function, which is particularly important in children.
Murphy
J V
JV
Division of Neurosciences, Children's Mercy Hospital, Kansas City, Missouri 64108.
D000927:Anticonvulsants / Q000008:administration & dosage; D002648:Child; D004359:Drug Therapy, Combination; D004831:Epilepsies, Myoclonic / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D006801:Humans; D007223:Infant; D003294:Seizures, Febrile / Q000188:drug therapy*; D013036:Spasms, Infantile / Q000188:drug therapy; D014635:Valproic Acid / Q000008:administration & dosage* / Q000627:therapeutic use
D000927:Anticonvulsants; D014635:Valproic Acid